- Home
- GITS vs THAR Comparison
GITS vs THAR Comparison
Compare GITS & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | THAR |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 83.1M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GITS | THAR |
|---|---|---|
| Price | $1.21 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 15.2K | ★ 287.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,867.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.95 |
| 52 Week High | $9.78 | $9.08 |
Technical Indicators
Market Signals| Indicator | GITS | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 30.35 | 41.25 |
| Support Level | $1.25 | $2.36 |
| Resistance Level | $1.34 | $2.75 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 15.46 | 8.51 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.